TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

To join this study, you would need to have been officially diagnosed with hATTR that causes nerve damage (polyneuropathy) and have a specific change in your TTR gene. Your nerve problems should be within a certain range of severity, and you should generally be able to manage your daily activities.

There are also some reasons why you might not be able to join. For example, if you've had a liver transplant or are likely to need one soon, you wouldn't be eligible. The study also can't include people who have other types of amyloidosis, severe heart failure, or certain problems with their liver or kidneys. If you have other known causes for nerve problems that aren't related to hATTR, you also wouldn't be able to take part.

These rules are in place to help make sure the study is safe for everyone involved and that the results are clear and accurate. Your study doctor would carefully check all these points with you.

If you decide to take part in this study, you will be given one of the study medicines, either Nucresiran or Vutrisiran. You will need to attend regular visits to the study clinic over a period of time. These visits will involve various assessments to check your health and how the medicine is affecting you. This might include physical exams, blood tests, urine tests, checks of your nerve function, and questions about your quality of life and how you're feeling. You'll be closely monitored by the study team throughout. The total duration of your participation in the study, including follow-up, would be fully explained to you before you agree to join.